Modulight Biotherapeutics Raises $12.2M to Advance Optogenetic Therapy for Neurological Disorders
Key Insights
Modulight Biotherapeutics (search) secured $12.2 million in seed financing led by Jibe Ventures (search) and LocalGlobe (search) to develop optogenetic technology for neurological disorders.
The company's platform uses eOPN3 (search), an inhibitory opsin licensed from Weizmann Institute, which stops neural activity when activated by red light to treat pathological electrical circuits.
Trigeminal pain (search) will be the first clinical indication pursued, with the company preparing for FDA pre-IND meetings and anticipating IND-enabling studies completion by 2027.
Modulight Biotherapeutics (search) has raised $12.2 million in seed financing to advance its optogenetic technology platform targeting neurological disorders, marking a significant step forward for precision neurostimulation therapies. The seed round was led by Jibe Ventures (search) and LocalGlobe (search), with participation from Nexus Neurotech Ventures, RedSeed VC, and Secret Chord Ventures.
Novel Optogenetic Platform Targets Pathological Neural Circuits
The neuron-targeting startup's platform centers on eOPN3 (search), an inhibitory opsin originally designed for clinical use by the Weizmann Institute of Science. Modulight has secured an exclusive license for this technology from Yeda (search), the commercial arm of the institute. When activated by light, eOPN3 stops neural activity at target synapses, severing the pathway of communication between neurons.
This mechanism proves particularly valuable for disorders characterized by pathological electrical circuits, including severe chronic pain (search), epilepsy (search), and movement disorders (search)—the primary indications Modulight is targeting with its platform. The company's approach represents a departure from current techniques that act broadly, affecting large brain regions and networks indiscriminately.
Strong Preclinical Data Supports Clinical Translation
Modulight's preclinical studies demonstrate high efficacy of eOPN3 (search)-based treatment across multiple animal models of pain, epilepsy (search), and movement disorders (search). The company leverages red light activation, which offers superior tissue penetration compared to other wavelengths, enabling both non-invasive and minimally invasive illumination approaches in the human brain.
CEO Yotam Eldar confirmed that trigeminal pain (search), a severe and often drug-resistant facial pain disorder, will serve as the first clinical indication. "Trigeminal pain conditions allow for minimally invasive light delivery, which accelerates clinical translation and accessibility," Eldar explained.
Regulatory Pathway and Timeline
The company is currently preparing for a pre-investigational new drug (IND) meeting with the FDA to discuss its preclinical program, manufacturing plans, and regulatory pathway. With chemistry, manufacturing, and controls (CMC) and regulatory processes already underway, Modulight anticipates completing IND-enabling studies in 2027, followed by IND submission.
Addressing Unmet Medical Needs in Neurology
While optogenetic-based therapeutics are being pursued by other companies, no products have yet received FDA approval, positioning Modulight in an emerging but unproven therapeutic space. The funding will help accelerate the platform's development and advance the pipeline toward clinical trials.
Eldar emphasized the technology's precision advantage: "Modulight has an exclusive licence for eONP3 technology from Yeda (search). Importantly, eOPN3 (search) can be activated by red light, which has better tissue penetration and allows for both non-invasive and minimally invasive illumination approaches in the large human brain."
The company positions itself as part of a wave of startups pursuing more targeted approaches to neurological treatment, contrasting with traditional pharmaceutical interventions and neurorehabilitation that often lack precision in addressing specific neural circuits.